WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Novo vs. Lilly: Q2's cardiometabolic grudge match — Warptech Lab News

Storia in 5 fonti

Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.

Raccontata da

independent.co.uk

biopharmadive.com

fiercepharma.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.

Timeline cronologica

lunedì 3 agosto 2026·independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
martedì 4 agosto 2026·endpoints.news
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.

biopharmadive.com

1 g fa

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Leggi questa versione → originale

independent.co.uk2 g fa

GLP-1 battle heats up again as Novo claws its way back into race with Lilly

The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market

Leggi questa versione → originale

investors.com1 g fa

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Leggi questa versione → originale

fiercepharma.com20 h fa

Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom

Eli Lilly reported $98 million in second-quarter sales fo | Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging far behind rival Novo Nordisk's Wegovy…

Leggi questa versione → originale

martedì 4 agosto 2026·

investors.com

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

mercoledì 5 agosto 2026·

biopharmadive.com

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

mercoledì 5 agosto 2026·

fiercepharma.com

Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom

Eli Lilly reported $98 million in second-quarter sales fo | Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging…

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com